| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:EBI-907
CAS:1581764-31-9
Package:1removed
|
|
| | EBI-907 Basic information |
| Product Name: | EBI-907 | | Synonyms: | EBI-907;1-Propanesulfonamide, N-[2-chloro-3-(1-cyclopropyl-8-methoxy-3H-pyrazolo[3,4-c]isoquinolin-7-yl)-4-fluorophenyl]-3-fluoro- | | CAS: | 1581764-31-9 | | MF: | C23H21ClF2N4O3S | | MW: | 506.95 | | EINECS: | | | Product Categories: | | | Mol File: | 1581764-31-9.mol |  |
| | EBI-907 Chemical Properties |
| Boiling point | 685.6±65.0 °C(Predicted) | | density | 1.58±0.1 g/cm3(Predicted) | | pka | 7.09±0.10(Predicted) |
| | EBI-907 Usage And Synthesis |
| Description | EBI-907 is a highly potent and orally efficacious B-RafV600E inhibitor. EBI-907 displays a low single-digit nanomolar activity (IC50 = 4.9 nM), which is >10-fold more potent than Vemurafenib (IC50 = 59 nM). EBI-907 also exhibits high potency in selectively inhibiting the proliferation of BRAF (V600E)-dependent cell lines (A375 and Colo205) and cellular Erk phosporylation, with superior activity to Vemurafenib. EBI-907, displaying potent activity against a number of important oncogenic kinases including BRK, FGFR1, c-Kit, and PDGFRb. | | Uses | EBI-907 is an orally active and highly potent B-RafV600E inhibitor. EBI-907 demonstrates excellent A375 and Colo-205 cellular antiproliferative activity with IC50 values of 13 nM and 14 nM, respectively. EBI-907 can also cause tumor regression in a B-RafV600E-dependent Colo-205 tumor xenograft model of mice. EBI-907 is promising for research of melanoma and B-RafV600E associated cancers[1][2]. | | References | [1] Lu B, et al. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers. Bioorg Med Chem Lett. 2016 Feb 1;26(3):819-823. DOI:10.1016/j.bmcl.2015.12.086
[2] Zhang J, et al. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol Ther. 2016;17(2):199-207. DOI:10.1080/15384047.2016.1139231 |
| | EBI-907 Preparation Products And Raw materials |
|